Netherlands

BMI View: Despite the combined effects of the Medicines Pricing Act and health insurers' preference policies creating downward pressure on prescription medicine prices, we believe... 2012-04-23

BMI view : Lipitor (atorvastatin)'s patent expiration brings significant revenue-earning opportunities for Ranbaxy Laboratories in Europe, particularly as cash-strapped governments... 2012-03-15

BMI View: Drug companies will face many challenges in Western Europe over the next decade. Our forecast is underpinned by the poor state of public finances across the eurozone, which... 2011-04-19

BMI View: Despite the threat of austerity measures, the government's focus on cost-containment within the pharmaceuticals and healthcare sector and the impact of generic competition... 2011-04-18

BMI Core View: The uptake of generic drugs following patent expiries will become swifter. This trend will reduce costs for governments, out-of-pocket payers and insurance companies,... 2011-02-16

BMI View: Deficits remain a key challenge for the majority of governments across Europe. While many industries may see only limited downside risks from the situation, the pharmaceuticals... 2010-10-21

Despite a compound annual growth rate (CAGR) of 3.61% in local currency terms and of 6.1% in US dollar terms from 2004-2009, BMI's outlook for the Netherlands' patented drug market... 2010-01-19